Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Propylparaben. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | ESR1 | P03372 | 3/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | STS | P08842 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propylparaben SCHEMBL48862 | 0.96 | ALDH1A1 (0.68) | ALDH1A1TSHRESR1TDP1CHRM1 | |
| Propylparaben SCHEMBL8361958 | 0.95 | ALDH1A1 (0.66) | ALDH1A1TSHRESR1TDP1CHRM1 | |
| Propylparaben SCHEMBL11658475 | 0.91 | ALDH1A1 (0.62) | ALDH1A1TSHRESR1TDP1CHRM1 | |
| Propylparaben SCHEMBL7607113 | 0.90 | ALDH1A1 (0.60) | ALDH1A1TSHRESR1TDP1CHRM1 | |
| Propylparaben SCHEMBL2812584 | 0.90 | ESR1 (0.81) | ALDH1A1TSHRESR1TDP1CHRM1 | |
| SCHEMBL49950 | 0.88 | ALDH1A1 (0.84) | ALDH1A1TSHRESR1TDP1CHRM1 | |
| SCHEMBL27647501 | 0.86 | ALDH1A1 (0.81) | ALDH1A1TSHRESR1TDP1CHRM1 | |
| SCHEMBL27647586 | 0.86 | ALDH1A1 (0.81) | ALDH1A1TSHRESR1TDP1CHRM1 | |
| SCHEMBL28758641 | 0.86 | ALDH1A1 (0.81) | ALDH1A1TSHRESR1TDP1CHRM1 | |
| Methane SCHEMBL27699232 | 0.86 | ALDH1A1 (0.81) | ALDH1A1TSHRESR1TDP1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114931548-A | Preparation method of gendarussa wine gel paste | 季华实验室 | 2022-08-23 | — | — | CN | claimed |
| CN-107635589-A | Essentially antimicrobial porous matrix composites and methods of making the same | 约翰·保罗·威尔逊 | 2018-01-26 | — | — | CN | claimed |
| US-9456970-B2 | Dermatological compositions and methods | UPSHER-SMITH LABORATORIES, INC. (US) | 2016-10-04 | — | — | US | claimed |
| US-20160000672-A1 | DERMATOLOGICAL COMPOSITIONS AND METHODS | UPSHER-SMITH LABORATORIES, INC. (US) | 2016-01-07 | — | — | US | claimed |
| CN-102784095-A | Glycyrrhetinic acid hydrogel preparation and preparation method and application thereof | CHINESE ACAD TECH INST PHYSICS | 2012-11-21 | — | — | CN | claimed |
| EP-2482816-A1 | TOPICAL COMPOSITIONS OF OPIOID ANTAGONISTS AND METHODS FOR TREATING SKIN CONDITIONS THEREWITH | AK Kimya Ithalat-Ihracat Ve Sanayii A.S. (TR) | 2012-08-08 | — | — | EP | claimed |
| US-20110288172-A1 | DERMATOLOGICAL COMPOSITIONS AND METHODS | UPSHER-SMITH LABORATORIES, INC. (US) | 2011-11-24 | — | — | US | claimed |
| CN-101316580-B | Fexofenadine suspension formulation | SANOFI AVENTIS US LLC | 2011-11-16 | — | — | CN | claimed |
| US-8013017-B2 | Dermatological compositions and methods | UPSHER-SMITH LABORATORIES, INC. (US) | 2011-09-06 | — | — | US | claimed |
| US-20110082167-A1 | TOPICAL COMPOSITIONS OF OPIOID ANTAGONISTS AND METHODS FOR TREATING SKIN CONDITIONS THEREWITH | MUSTAFA NEVZAT ILAC SANAYII A.S. (TR) | 2011-04-07 | — | — | US | claimed |
| WO-2011040894-A1 | TOPICAL COMPOSITIONS OF OPIOID ANTAGONISTS AND METHODS FOR TREATING SKIN CONDITIONS THEREWITH | MUSTAFA NEVZAT ILAÇ SANAYII A.Ş. (TR) | 2011-04-07 | — | — | WO | claimed |
| US-20090247632-A1 | DERMATOLOGICAL COMPOSITIONS AND METHODS | UPSHER-SMITH LABORATORIES, INC. (US) | 2009-10-01 | — | — | US | claimed |
| CN-101316580-A | Fexofenadine suspension formulation | SANOFI AVENTIS US LLC (US) | 2008-12-03 | — | — | CN | claimed |
| US-20050059644-A1 | Dermatological compositions and methods | UPSHER-SMITH LABORATORIES, INC. (US) | 2005-03-17 | — | — | US | claimed |
| US-20030017181-A1 | Dermatological compositions and methods | UPSHER-SMITH LABORATORIES, INC. | 2003-01-23 | — | — | US | claimed |
| WO-2002096374-A2 | DERMATOLOGICAL COMPOSITIONS AND METHODS COMPRISING ALPHA-HYDROXY ACIDS OR DERIVATIVES | UPSHER-SMITH LABORATORIES, INC. (US) | 2002-12-05 | — | — | WO | claimed |
| EP-4724590-A1 | ADENO-ASSOCIATED VIRUS FORMULATIONS | 4D Molecular Therapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12553062-B2 | AAV compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20030017181-A1 | Dermatological compositions and methods | UPSHER-SMITH LABORATORIES, INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2002096374-A2 | DERMATOLOGICAL COMPOSITIONS AND METHODS COMPRISING ALPHA-HYDROXY ACIDS OR DERIVATIVES | UPSHER-SMITH LABORATORIES, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082167-A1 | TOPICAL COMPOSITIONS OF OPIOID ANTAGONISTS AND METHODS FOR TREATING SKIN CONDITIONS THEREWITH | OPRK1, OPRL1, OPRD1 | ALDH1A1 413/4885TSHR 4367/4885ESR1 470/4885 |
| US-12553062-B2 | AAV compositions | PRDM9, H1-10, SLC20A1 | ALDH1A1 2913/4885TSHR 2675/4885ESR1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.